Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:LCTX NASDAQ:OPT NASDAQ:OTLK NYSE:SQZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLCTXLineage Cell Therapeutics$1.37$1.61$0.44▼$2.09$341.54M1.61.25 million shs1.17 million shsOPTOpthea$3.41$3.41$1.79▼$6.30$524.84M1.12N/AN/AOTLKOncobiologics$0.22+2.6%$0.31$0.16▼$3.39$22.57M0.324.87 million shs3.21 million shsSQZSQZ Biotechnologies$0.02$0.02$0.25▼$3.56$708K2.34455,220 shs400 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLCTXLineage Cell Therapeutics0.00%-9.27%-11.04%-19.41%+208.56%OPTOpthea0.00%0.00%0.00%0.00%0.00%OTLKOncobiologics0.00%-13.72%-13.75%-49.77%-84.70%SQZSQZ Biotechnologies0.00%0.00%0.00%0.00%-14.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLCTXLineage Cell Therapeutics$1.37$1.61$0.44▼$2.09$341.54M1.61.25 million shs1.17 million shsOPTOpthea$3.41$3.41$1.79▼$6.30$524.84M1.12N/AN/AOTLKOncobiologics$0.22+2.6%$0.31$0.16▼$3.39$22.57M0.324.87 million shs3.21 million shsSQZSQZ Biotechnologies$0.02$0.02$0.25▼$3.56$708K2.34455,220 shs400 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLCTXLineage Cell Therapeutics0.00%-9.27%-11.04%-19.41%+208.56%OPTOpthea0.00%0.00%0.00%0.00%0.00%OTLKOncobiologics0.00%-13.72%-13.75%-49.77%-84.70%SQZSQZ Biotechnologies0.00%0.00%0.00%0.00%-14.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLCTXLineage Cell Therapeutics 3.00Buy$6.25356.20% UpsideOPTOpthea 1.00SellN/AN/AOTLKOncobiologics 2.00Hold$4.501,933.44% UpsideSQZSQZ Biotechnologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SQZ, OTLK, LCTX, and OPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026LCTXLineage Cell Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/28/2026LCTXLineage Cell Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.003/27/2026OTLKOncobiologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/25/2026LCTXLineage Cell Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $4.003/24/2026LCTXLineage Cell Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.003/11/2026OTLKOncobiologics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $6.003/6/2026LCTXLineage Cell Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/6/2026LCTXLineage Cell Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $3.002/18/2026OTLKOncobiologics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral2/18/2026OTLKOncobiologics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral2/9/2026LCTXLineage Cell Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLCTXLineage Cell Therapeutics$14.56M23.46N/AN/A$0.19 per share7.21OPTOpthea$25K20,993.46N/AN/A($1.31) per share-2.60OTLKOncobiologics$1.35M17.15N/AN/A($0.60) per share-0.37SQZSQZ Biotechnologies$18.16M0.04N/AN/A$1.94 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLCTXLineage Cell Therapeutics-$63.53M-$0.12N/AN/AN/A-436.47%-76.13%-35.53%5/12/2026 (Estimated)OPTOpthea-$162.79MN/AN/AN/AN/AN/AN/AN/AN/AOTLKOncobiologics-$62.42M-$2.62N/AN/AN/AN/AN/A-293.47%5/14/2026 (Estimated)SQZSQZ Biotechnologies-$79.46M-$2.61N/AN/AN/A-369.96%-119.83%-59.90%N/ALatest SQZ, OTLK, LCTX, and OPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q2 2026OTLKOncobiologics-$0.12N/AN/AN/A$4.39 millionN/A5/12/2026Q1 2026LCTXLineage Cell Therapeutics-$0.02N/AN/AN/A$3.60 millionN/A3/5/2026Q4 2025LCTXLineage Cell Therapeutics-$0.07$0.0040+$0.0740$0.0040$1.96 million$6.61 million2/17/2026Q1 2026OTLKOncobiologics-$0.17-$0.22-$0.05-$0.38$3.14 million($1.21) millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLCTXLineage Cell TherapeuticsN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/ASQZSQZ BiotechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLCTXLineage Cell TherapeuticsN/A5.205.20OPTOptheaN/A0.220.22OTLKOncobiologicsN/A0.350.28SQZSQZ BiotechnologiesN/A3.503.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLCTXLineage Cell Therapeutics62.47%OPTOpthea55.95%OTLKOncobiologics11.20%SQZSQZ Biotechnologies38.51%Insider OwnershipCompanyInsider OwnershipLCTXLineage Cell Therapeutics26.80%OPTOpthea3.20%OTLKOncobiologics2.80%SQZSQZ Biotechnologies16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLCTXLineage Cell Therapeutics60249.30 million182.49 millionNot OptionableOPTOpthea8153.91 million165.53 millionNot OptionableOTLKOncobiologics20104.61 million101.69 millionOptionableSQZSQZ Biotechnologies1,62029.49 million24.77 millionNot OptionableSQZ, OTLK, LCTX, and OPT HeadlinesRecent News About These CompaniesArsenal Yards attracts another life sciences tenantApril 23, 2026 | bizjournals.comFinancial Comparison: SQZ Biotechnologies (NYSE:SQZ) vs. Cortexyme (NASDAQ:CRTX)March 22, 2026 | defenseworld.netDSerica Energy reveals impact of Triton downtime, eyes volume recovery “soonâ€August 5, 2025 | proactiveinvestors.co.ukSQZB SQZ Biotechnologies Company - Seeking AlphaJuly 9, 2025 | seekingalpha.comSerica Energy shares drop as Triton suspended until mid-MarchFebruary 18, 2025 | proactiveinvestors.co.ukSerica Energy says 2025 outlook is ‘promising'January 21, 2025 | proactiveinvestors.co.ukSerica Energy expects to remedy “clearly disappointing†recent production performanceJanuary 7, 2025 | proactiveinvestors.co.ukSQZ Biotechnologies Co Ordinary SharesDecember 23, 2024 | morningstar.comMPortal Biotechnologies Announces Over 50 Partnerships and Oversubscribed $7M Seed Round Led by IA VenturesDecember 19, 2024 | finance.yahoo.comGlobal Short-Acting Insulin Market is Expected to Cross ~USD 9 Billion by 2030 | DelveInsightSeptember 5, 2024 | prnewswire.co.ukPSTEMCELL Launches Novel Cell-Engineering CellPore™ Transfection SystemAugust 1, 2024 | valdostadailytimes.comVWhat is the price tag to keep the biotech engine humming in Massachusetts?July 23, 2024 | msn.comSQZ Biotechnologies Company (SQZB)May 22, 2024 | finance.yahoo.comSqz Bio (SQZB) Earnings Dates & ReportsMay 8, 2024 | investing.comVC funding update: who raised money in March?April 1, 2024 | bizjournals.comSQZ, Portal founder Armon Sharei on starting over in biotechMarch 26, 2024 | biopharmadive.comBPortal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VCMarch 19, 2024 | finance.yahoo.comSQZ, months after 80% layoffs, opts for liquidation and $11.8M asset fire sale to StemcellMarch 1, 2024 | fiercebiotech.comFRx Rundown: Gilead Sciences, Latigo Biotherapeutics, Exscientia and moreFebruary 16, 2024 | mmm-online.comMSQZB SQZ Biotechnologies CompanyDecember 28, 2023 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Up 775% in 5 Months, How Much Higher Can Syntec Optics Go?By Thomas Hughes | April 21, 2026SQZ, OTLK, LCTX, and OPT Company DescriptionsLineage Cell Therapeutics NYSEAMERICAN:LCTX$1.37 0.00 (0.00%) Closing price 05/8/2026 04:10 PM EasternExtended Trading$1.37 +0.00 (+0.15%) As of 05/8/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.Opthea NASDAQ:OPTOpthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Oncobiologics NASDAQ:OTLK$0.22 +0.01 (+2.60%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.22 +0.00 (+1.22%) As of 05/8/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.SQZ Biotechnologies NYSE:SQZ$0.02 0.00 (0.00%) As of 05/8/2026SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
